Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

discontinuation of therapy. Some patients experienced ongoing or new serious adverse reactions during the 6-month follow-up period. Discontinuations for adverse events were 15% and were related to known interferon effects of psychiatric, systemic (e.g., fatigue, headache), or gastrointestinal adverse reactions. Dose modifications due to adverse reactions occurred in 29% of patients.

Most common adverse reactions with PEGINTRON/REBETOL (weight-based) combination therapy were psychiatric which occurred among 68-69% of patients. These psychiatric adverse reactions included most commonly depression, irritability, and insomnia, each reported by approximately 30-40% of subjects in all treatment groups. Suicidal behavior (ideation, attempts and suicides) occurred in 2% of all patients during treatment or during follow-up after treatment cessation. PEGINTRON induced fatigue or headache in approximately two-thirds of patients, with fever or rigors in approximately half of the patients. The severity of some of these systemic symptoms (e.g., fever and headache) tends to decrease as treatment continues. There was a 23-24% incidence overall for injection site reactions or inflammation.

Individual serious adverse reactions occurred at a frequency less than or equal to 1% and included suicide attempt, suicidal ideation, severe depression; psychosis, aggressive reaction, relapse of drug addiction/overdose; nerve palsy (facial, oculomotor); cardiomyopathy, myocardial infarction, angina, pericardial effusion, retinal ischemia, retinal artery or vein thrombosis, blindness, decreased visual acuity, optic neuritis, transient ischemic attack, supraventricular arrhythmias, loss of consciousness; neutropenia, infection (sepsis, pneumonia, abscess, cellulitis); emphysema, bronchiolitis obliterans, pleural effusion, gastroenteritis, pancreatitis, gout, hyperglycemia, hyperthyroidism and hypothyroidism, autoimmune thrombocytopenia with or without
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015  SynCardia Systems, Inc. has received ... clinical study on the effective use of its 50cc ... The FDA approval will allow ... 30 heart failure patients. Patients enrolled in this study ... a bridge to a donor heart transplant. (Caution-In ...
(Date:3/31/2015)... ALPHARETTA, Ga. , March 31, 2015   ... Health Care, today announced it was awarded a new ... line of face masks. Effective March 1, 2015, Halyard,s ... masks with SO SOFT* lining, will be available to ... as well as 15,000 ambulatory surgery centers, physician practices ...
(Date:3/31/2015)... MedSpring Urgent Care is pleased to announce the opening ... area of Upper Greenville. The center – located at 4844 Greenville ... location. Knox - Henderson , its ... since opening last fall. Additional Dallas metroplex ... and Las Colinas neighborhoods this summer. "We ...
Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2
... Life Technologies Corporation (NASDAQ: LIFE ) ... with GlaxoSmithKline Biologicals S.A. (GSK) to develop a diagnostic ... GSK candidate cancer immunotherapy. Specifically, Life will develop a ... candidate designed to identify patients likely to benefit from ...
... (Cayman) Inc. (NYSE: WX ), a leading ... operations in China and the United States, today announced ... quarter of 2011 after the New York Stock Exchange ... Friday morning, November 11, 2011 Shanghai time). The earnings ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2
(Date:3/31/2015)... When SIGVARIS launched the EVERSHEER compression therapy line in ... date. Women immediately fell in love with the line’s transparency ... love EVERSHEER with the launch of a new on-trend, limited-edition ... pairs perfectly with a variety of navy, gray, black, pink, ... add a hint of spring to their wardrobe and keep ...
(Date:3/31/2015)... India Network Foundation , sponsor ... travel advisory to all USA bound international travelers on ... States are higher than many other countries and procedures ... example, a coronary artery bypass graft costs about ... $34,358 . Visitors are advised to get a ...
(Date:3/31/2015)... California (PRWEB) March 31, 2015 ... company that specializes in providing online solutions ... announced today it has achieved full accreditation ... Healthcare Network Accreditation Program (HNAP) from the ... , EHNAC’s HNAP accreditation runs in two-year ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 A' Design ... design project Bruker EVOQ by Daniel Dion has been ... Award in Scientific Instruments, Medical Devices and Research ... Daniel Dion, the creative mind behind the award winning ... MS - developed under the direction of Dr. Rohan ...
(Date:3/31/2015)... 31, 2015 A team of Italian ... with anti-cancer properties, into mesothelioma cancer cells. Surviving Mesothelioma ... on its website. Click here to read it ... yellow color to the spice turmeric, has limited value ... Biomaterials experts at Università di Napoli Federico II are ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2Health News:New Research Reveals Novel Delivery Method for Potential Mesothelioma Treatment, According to Surviving Mesothelioma 2
... A Research was conducted by Kenneth Norman, Sean Polyn and ... It was funded by the National Institute of Health. It ... events that has occurred in the past. This could help ... is of great importance in the field on psychology and ...
... of death before voting had an impact on their voting ... policy reports that the fear of death// had an impact ... the fear of death caused by Osama bin laden tape ... of the voters which made them vote in favor George ...
... Human Organ Transplant Act to prevent commercialization of human organs, ... the Indian health care system//. The recent report of bilateral ... Bihar has created much panic in the State. ... Patna Medical College Hospital Friday after battling for his life ...
... AIDS victims who have been trying to gain special access to ... 125) can now rejoice as the Health Canada // has now ... clinical trial. ,Dr. Montaner, an AIDS drugs specialist with ... has been trying hard to bring the two unapproved drugs into ...
... a Christmas gift for a large number of obese people ... condition is minimum sweat to the body.// ,The answer ... associate professor of medicine and founding member of the Harvard ... plan. It requires less of the strenuous exercises that most ...
... new cases have been found in Britain, with renewed ... take anti-malarial medication.// ,The warning from the ... Britain were diagnosed with malaria. ,There have ... two people returning from Gambia died. None of the ...
Cached Medicine News:Health News:Mystery behind Brain activity during recalling events disentangled 2Health News:Both Kidneys Robbed From A Poor Rickshaw Driver In Bihar 2Health News:Five AIDS Patients To Receive Experimental Anti-retroviral Drugs 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: